Non-islet cell tumour-induced hypoglycaemia: A review of the literature including two new cases

Endocrine-Related Cancer

Volumn 14, Issue 4, 2007, Pages 979-993

  De Groot, Jan Willem B ^a   Rikhof, Bart ^a   Van Doorn, Jaap ^b   Bilo, Henk J G ^a,c   Alleman, Maarten A ^a   Honkoop, Aafke H ^a   Van Der Graaf, Winette T A ^d  

^a Isala Klinieken ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; CARBAMAZEPINE; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE; GLUCAGON; GLUCOCORTICOID; GLUCOSE; GROWTH HORMONE; OCTREOTIDE; PREDNISOLONE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOSTATIN; STEROID;

ADULT; AGED; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMATOSE PATIENT; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; DISEASE COURSE; DRUG UPTAKE; EPILEPSY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GLUCONEOGENESIS; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; HYPOGLYCEMIA; IN SITU HYBRIDIZATION; INCIDENCE; INSULIN RELEASE; MAINTENANCE DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NON ISLET CELL TUMOR HYPOGLYCEMIA; POSITRON EMISSION TOMOGRAPHY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SYMPTOM; TUMOR VOLUME;

AGED, 80 AND OVER; BLOOD GLUCOSE; FEMALE; HUMANS; HYPOGLYCEMIA; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RNA, MESSENGER;

EID: 39149106133     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0161     Document Type: Review

References (105)

1. Axelrod L & Ron D 1988 Insulin-like growth factor II and the riddle of tumor-induced hypoglycemia. New England Journal of Medicine 319 1477-1479.
2. Baserga R, Peruzzi F & Reiss K 2003 The IGF-1 receptor in cancer biology. International Journal of Cancer 107 873-877.
3. Baxter RC 1996 The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia. Hormone Research 46 195-201.
4. Baxter RC & Daughaday WH 1991 Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. Journal of Clinical Endocrinology and Metabolism 73 696-702.
5. Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ & Braund W 1995 Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. Journal of Clinical Endocrinology and Metabolism 80 2700-2708.
6. Belfiore A 2007 The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Current Pharmaceutical Design 13 671-686.
7. Bertherat J, Logie A, Gicquel C, Mourrieras F, Luton JP & Le Bouc Y 2000 Alterations of the 11p15 imprinted region and the IGFs system in a case of recurrent non-islet-cell tumour hypoglycaemia (NICTH). Clinical Endocrinology 53 213-220.
8. de Boer J, Jager PL, Wiggers T, Nieboer P, Wymenga AN, Pras E, Hoogenberg K, Sleijfer DT, Suurmeijer AJ & van der Graaf WT 2006 The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient. International Journal of Clinical Oncology 11 478-481.
9. Bond JJ, Meka S & Baxter RC 2000 Binding characteristics of pro-insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to -6. Journal of Endocrinology 165 253-260.
10. Bourcigaux N, Arnault-Ouary G, Christol R, Perm L, Charbonnel B & Le Bouc Y 2005 Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clinical Therapeutics 27 246-251.
11. van Buul-Offers SC 1996 Insulin-like growth factor-II in the cycle of life. Biomedical Reviews 5 65-71.
12. Cebon J 2006 Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer 95 853-861.
13. Christofori G, Naik P & Hanahan D 1995 Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during beta-cell tumorigenesis. Nature Genetics 10 196-201.
14. Chung J & Henry RR 1996 Mechanisms of tumor-induced hypoglycemia with intraabdominal hemangiopericytoma. Journal of Clinical Endocrinology and Metabolism 81 919-925.
15. Daughaday WH 1990 The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 127 1-4.
16. Daughaday WH 2004 Free insulin-like growth factor (IGF) in disorders of IGF binding protein 3 complex formation. Journal of Clinical Endocrinology and Metabolism 89 3-5.
17. Daughaday WH & Kapadia M 1989 Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. PNAS 86 6778-6782.
18. Daughaday WH & Rotwein P 1989 Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrine Reviews 10 68-91.
19. Daughaday WH & Trivedi B 1992a Heterogeneity of serum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-II E domain: description of a free E domain peptide in serum. Journal of Clinical Endocrinology and Metabolism 75 641-645.
20. Daughaday WH & Trivedi B 19926 Measurement of derivatives of proinsulin-like growth factor-II in serum by a radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia. Journal of Clinical Endocrinology and Metabolism 75 110-115.
21. Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M & Rotwein P 1988 Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. New England Journal of Medicine 319 1434-1440.
22. Daughaday WH, Wu JC, Lee SD & Kapadia M 1990 Abnormal processing of pro-IGF-II in patients with hepatoma and in some hepatitis B virus antibody-positive asymptomatic individuals. Journal of Laboratory and Clinical Medicine 116 555-562.
23. Daughaday WH, Trivedi B & Baxter RC 1993 Serum 'big insulin-like growth factor II' from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing. PNAS 90 5823-5827.
24. Daughaday WH, Trivedi B & Baxter RC 1995 Abnormal serum IGF-II transport in non-islet cell tumor hypoglycemia results from abnormalities of both IGF-II binding protein-3 and acid labile subunit and leads to elevation of serum free IGF-II. Endocrine 3 425-428.
25. Denley A, Cosgrove LJ, Booker GW, Wallace JC & Forbes BE 2005 Molecular interactions of the IGF system. Cytokine and Growth Factor Reviews 16 421-439.
26. van Doorn J, Hoogerbrugge CM, Koster JG, Bloemen RJ, Hoekman K, Mudde AH & van Buul-Offers SC 2002 Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia. Clinical Chemistry 48 1739-1750.
27. van Doorn J, Gilhuis HJ, Koster JG, Wesseling P, Reddingius RE, Gresnigt MG, Bloemen RJ, van Muijen GN & van Buul-Offers SC 2004 Differential patterns of insulin-like growth factor-I and -II mRNA expression in medulloblastoma. Neuropathology and Applied Neurobiology 30 503-512.
28. Drake WM, Miraki F, Siddiqi A, Yateman M, Barnes NC, Camacho-Hubner C & Monson JP 1998 Dose-related effects of growth hormone on IGF-I and IGF-binding protein-3 levels in non-islet cell tumour hypoglycaemia. European Journal of Endocrinology 139 532-536.
29. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP & Rauscher FJ III 1992 Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257 674-678.
30. Duguay SJ, Jin Y, Stein J, Duguay AN, Gardner P & Steiner DF 1998 Post-translational processing of the insulin-like growth factor-2 precursor. Analysis of O-glycosylation and endoproteolysis. Journal of Biological Chemistry 273 18443-18451.
31. Dupont J, Pierre A, Froment P & Moreau C 2003 The insulin-like growth factor axis in cell cycle progression. Hormone and Metabolic Research 35 740-750.
32. Eastman RC, Carson RE, Orloff DG, Cochran CS, Perdue JF, Rechler MM, Lanau F, Roberts CT Jr, Shapiro J, Roth J et al. 1992 Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. Journal of Clinical Investigation 89 1958-1963.
33. Falls JG, Pulford DJ, Wylie AA & Jirtle RL 1999 Genomic imprinting: implications for human disease. American Journal of Pathology 154 635-647.
34. Fehmann HC, Jehle P, Markus U & Goke B 1996 Functional active receptors for insulin-like growth factors-I (IGF-I) and IGF-II on insulin-, glucagon-, and somatostatin-producing cells. Metabolism 45 759-766.
35. Firth SM & Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews 23 824-854.
36. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A & Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 19 3278-3288.
37. Frystyk J, Skjaerbaek C, Zapf J & Orskov H 1998 Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia. Diabetologia 41 589-594.
38. Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y & Takano K 2006 Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Hormone and IGF Research 16 211-216.
39. Gama R, Teale JD & Marks V 2003 Best practice no 173: clinical and laboratory investigation of adult spontaneous hypoglycaemia. Journal of Clinical Pathology 56 641-646.
40. Gorden P, Hendricks CM, Kahn CR, Megyesi K & Roth J 1981 Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. New England Journal of Medicine 305 1452-1455.
41. Guler HP, Zapf J, Schmid C & Froesch ER 1989 Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinologica 121 753-758.
42. Hardouin S, Gourmelen M, Noguiez P, Seurin D, Roghani M, Le Bouc Y, Povoa G, Merimee TJ, Hossenlopp P & Binoux M 1989 Molecular forms of serum insulin-like growth factor (IGF)-binding proteins in man: relationships with growth hormone and IGFs and physiological significance. Journal of Clinical Endocrinology and Metabolism 69 1291-1301.
43. Hartog H, Wesseling J, Boezen HM & van der Graaf WT 2007 The insulin-like growth factor 1 receptor in cancer: old focus, new future. European Journal of Cancer 43 1895-1904.
44. Hizuka N, Fukuda I, Takano K, Okubo Y, Asakawa-Yasumoto K & Demura H 1998 Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocrine Journal 45 S61-S65.
45. Hodzic D, Delacroix L, Willemsen P, Bensbaho K, Collette J, Broux R, Lefebvre P, Legros JJ, Grooteclaes M & Winkler R 1997 Characterization of the IGF system and analysis of the possible molecular mechanisms leading to IGF-II overexpression in a mesothelioma. Hormone and Metabolic Research 29 549-555.
46. Hoekman K, van Doorn J, Gloudemans T, Hoekstra OS, Maassen JA, Vermorken JB, Wagstaff J & Pinedo HM 1994 Tumour-induced hypoglycaemia: a case report. Annals of Oncology 5 277-281.
47. Hoekman K, van Doorn J, Gloudemans T, Maassen JA, Schuller AG & Pinedo HM 1999 Hypoglycaemia associated with the production of insulin-like growth factor II and insulin-like growth factor binding protein 6 by a haemangiopericytoma. Clinical Endocrinology 51 247-253.
48. Hoff AO & Vassilopoulou-Sellin R 1998 The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer 82 1585-1592.
49. Holt RI, Teale JD, Jones JS, Quin JD, McGregor AM & Miell JP 1998 Gene expression and serum levels of insulin-like growth factors (IGFs) and IGF-binding proteins in a case of non-islet cell tumour hypoglycaemia. Growth Hormone and IGF Research 8 447-454.
50. Holt RI, Simpson HL & Sonksen PH 2003 The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabetic Medicine 20 3-15.
51. Horber FF, Marsh HM & Haymond MW 1991 Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans. Diabetes 40 141-149.
52. Hubbard SR & Miller WT 2007 Receptor tyrosine kinases: mechanisms of activation and signaling. Current Opinion in Cell Biology 19 117-123.
53. Hudgins WR, Hampton B, Burgess WH & Perdue JF 1992 The identification of O-glycosylated precursors of insulin-like growth factor II. Journal of Biological Chemistry 267 8153-8160.
54. Hunter SJ, Daughaday WH, Callender ME, McKnight JA, McIlrath EM, Teale JD & Atkinson AB 1994 A case of hepatoma associated with hypoglycaemia and overproduction of IGF-II (E-21): beneficial effects of treatment with growth hormone and intrahepatic adriamycin. Clinical Endocrinology 41 397-401.
55. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ & Piers DA 2001 Radiolabeled amino acids: basic aspects and clinical applications in oncology. Journal of Nuclear Medicine 42 432-445.
56. Jones JI & Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 16 3-34.
57. Khandwala HM, McCutcheon IE, Flyvbjerg A & Friend KE 2000 The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Reviews 21 215-244.
58. Khosla S, Hassoun AA, Baker BK, Liu F, Zein NN, Whyte MP, Reasner CA, Nippoldt TB, Tiegs RD, Hintz RL et al. 1998 Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. Journal of Clinical Investigation 101 2165-2173.
59. Khosla S, Ballard FJ & Conover CA 2002 Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. Journal of Clinical Endocrinology and Metabolism 87 3867-3870.
60. Kuenen BC, van Doorn J & Slee PH 1996 Non-islet-cell tumour induced hypoglycaemia: a case report and review of literature. Netherlands Journal of Medicine 48 175-179.
61. Lang CH, Nystrom GJ & Frost RA 2001 Tissue-specific regulation of IGF-I and IGF-binding proteins in response to TNFalpha. Growth Hormone and IGF Research 11 250-260.
62. LeRoith D 1997 Insulin-like growth factors. New England Journal of Medicine 336 633-640.
63. LeRoith D & Roberts CT Jr 2003 The insulin-like growth factor system and cancer. Cancer Letters 195 127-137.
64. LeRoith D, Werner H, Beitner-Johnson D & Roberts CT Jr 1995 Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews 16 143-163.
65. Lowe WL Jr, Roberts CT Jr, LeRoith D, Rojeski MT, Merimee TJ, Fui ST, Keen H, Arnold D, Mersey J, Gluzman S et al. 1989 Insulin-like growth factor-II in nonislet cell tumors associated with hypoglycemia: increased levels of messenger ribonucleic acid. Journal of Clinical Endocrinology and Metabolism 69 1153-1159.
66. Marks V & Teale JD 1998 Tumours producing hypoglycaemia. Endocrine-Related Cancer 5 111-129.
67. Megyesi K, Kahn CR, Roth J & Gorden P 1974 Hypoglycemia in association with extrapancreatic tumors: demonstration of elevated plasma NSILA-s by a new radioreceptor assay. Journal of Clinical Endocrinology and Metabolism 38 931-934.
68. Miraki-Moud F, Grossman AB, Besser M, Monson JP & Camacho-Hubner C 2005 A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia. Journal of Clinical Endocrinology and Metabolism 90 3819-3823.
69. Moller N, Blum WF, Mengel A, Hansen LB, Alberti KG & Schmitz O 1991 Basal and insulin stimulated substrate metabolism in tumour induced hypoglycaemia; evidence for increased muscle glucose uptake. Diabetologia 34 17-20.
70. Moller N, Frystyk J, Skjaerbaek C, Pedersen HB, Christensen C, Schmitz O, Gee A, Gjedde A, Zapf J & Orskov H 1996 Systemic and regional tumour metabolism in a patient with non-islet cell tumour hypoglycaemia: role of increased levels of free insulin-like growth factors. Diabetologia 39 1534-1535.
71. Morbois-Trabut L, Maillot F, De Widerspach-Thor A, Lamisse F & Couet C 2004 'Big IGF-II'-induced hypoglycemia secondary to gastric adenocarcinoma. Diabetes & Metabolism 30 276-279.
72. Nadler WA & Wolfer JH 1929 Hepatogenic hypoglycemia associated with primary liver cell carcinoma. Archives of Internal Medicine 44 700-705.
73. Nanayakkara PW, van Doorn J, van den Berg FG, van Groeningen CJ, Pinedo HM & Hoekman K 2002 Treatment of haemangiopericytoma-associated hypoglycaemia with embolisation. European Journal of Internal Medicine 13 340-343.
74. Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, Zwimpfer C, Figge AM, Flyvbjerg A, Lankisch PG, Blum WF et al. 2007 Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large- cell carcinoma of the lung. Journal of Clinical Endocrinology and Metabolism 92 1600-1605.
75. O'Dell SD & Day IN 1998 Insulin-like growth factor II (IGF-II). International Journal of Biochemistry and Cell Biology 30 767-771.
76. Perros P, Simpson J, Innes JA, Teale JD & McKnight JA 1996 Non-islet cell tumour-associated hypoglycaemia: 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clinical Endocrinology 44 727-731.
77. Phillips LS & Robertson DG 1993 Insulin-like growth factors and non-islet cell tumor hypoglycemia. Metabolism 42 1093-1101.
78. Pollak MN, Schernhammer ES & Hankinson SE 2004 Insulin-like growth factors and neoplasia. Nature Reviews. Cancer 4 505-518.
79. Rajaram S, Baylink DJ & Mohan S 1997 Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews 18 801-831.
80. Renehan AG, Toogood AA, Ryder WD, Jones J, Potten CS, O'Dwyer ST & Shalet SM 2001 Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. Clinical Endocrinology 55 469-475.
81. Reubi JC, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U & Wiedenmann B 1999 Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45 766-774.
82. Rinderknecht E & Humbel RE 1978a Primary structure of human insulin-like growth factor II. FEBS Letters 89 283-286.
83. Rinderknecht E & Humbel RE 19786 The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. Journal of Biological Chemistry 253 2769-2776.
84. Ron D, Powers AC, Pandian MR, Godine JE & Axelrod L 1989 Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. Journal of Clinical Endocrinology and Metabolism 68 701-706.
85. Samani AA, Yakar S, LeRoith D & Brodt P 2007 The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews 28 20-47.
86. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R & Belfiore A 2002 In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21 8240-8250.
87. Service FJ 1995 Hypoglycemic disorders. New England Journal of Medicine 332 1144-1152.
88. Shapiro ET, Bell GI, Polonsky KS, Rubenstein AH, Kew MC & Tager HS 1990 Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. Journal of Clinical Investigation 85 1672-1679.
89. Siddle K, Urso B, Niesler CA, Cope DL, Molina L, Surinya KH & Soos MA 2001 Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochemical Society Transactions 29 513-525.
90. Silveira LF, Bouloux PM, MacColl GS, Camacho-Hubner C & Miraki-Moud F 2002 Growth hormone therapy for non-islet cell tumor hypoglycemia. American Journal of Medicine 113 255-257.
91. Singh R, Grey A, Miller M, Gresnigt MG, Hoogerbrugge CM & van Doorn J 2006 Non-hyperinsulinemic hypoglycemia in a patient with a gastrointestinal stromal tumor. European Journal of Internal Medicine 17 127-129.
92. Sussenbach JS, Rodenburg RJ, Scheper W & Holthuizen P 1993 Transcriptional and post-transcriptional regulation of the human IGF-II gene expression. Advances in Experimental Medicine and Biology 343 63-71.
93. Teale JD & Marks V 1990 Inappropriately elevated plasma insulin-like growth factor II in relation to suppressed insulin-like growth factor I in the diagnosis of non-islet cell tumour hypoglycaemia. Clinical Endocrinology 33 87-98.
94. Teale JD & Marks V 1998 Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH). Clinical Endocrinology 49 491-498.
95. Teale JD & Wark G 2004 The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clinical Endocrinology 60 457-460.
96. Todd JF, Stanley SA, Roufosse CA, Bishop AE, Khoo B, Bloom SR & Meeran K 2003 A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes. Lancet 361 228-230.
97. Trivedi N, Mithal A, Sharma AK, Mishra SK, Pandey R, Trivedi B & Daughaday WH 1995 Non-islet cell tumour induced hypoglycaemia with acromegaloid facial and acral swelling. Clinical Endocrinology 42 433-435.
98. Tsuro K, Kojima H, Okamoto S, Yoshiji H, Fujimoto M, Uemura M, Yoshikawa M, Nakamura T, Kou S, Nakajima Y et al. 2006 Glucocorticoid therapy ameliorated hypoglycemia in insulin-like growth factor-II-producing solitary fibrous tumor. Internal Medicine 45 525-529.
99. Twigg SM, Kiefer MC, Zapf J & Baxter RC 1998 Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain. Journal of Biological Chemistry 273 28791-28798.
100. van der Ven LT, Roholl PJ, Gloudemans T, van Buul-Offers SC, Welters MJ, Bladergroen BA, Faber JA, Sussenbach JS & den Otter W 1997 Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. British Journal of Cancer 75 1631-1640.
101. Zachariah S, Brackenridge A, Shojaee-Moradie F, Camuncho-Hubner C, Umpleby AM & Russell-Jones D 2007 The mechanism of non-islet cell hypoglycaemia caused by tumour-produced IGF-II. Clinical Endocrinology 67 637-638.
102. Zapf J 1993 Role of insulin-like growth factor (IGF) II and IGF binding proteins in extrapancreatic tumour hypoglycaemia. Journal of Internal Medicine 234 543-552.
103. Zapf J, Walter H & Froesch ER 1981 Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. Journal of Clinical Investigation 68 1321-1330.
104. Zapf J, Schmid C, Guler HP, Waldvogel M, Hauri C, Futo E, Hossenlopp P, Binoux M & Froesch ER 1990 Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia. Journal of Clinical Investigation 86 952-961.
105. Zapf J, Futo E, Peter M & Froesch ER 1992 Can 'big' insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? Journal of Clinical Investigation 90 2574-2584.